Realeve Unveils Breakthrough Solution to Treat Central Nervous System Disorders Including Stroke and Cluster Headache; Bypasses Brain’s Natural Barrier to Deliver Therapeutics
Realeve has also been granted Breakthrough Device designation from the FDA with a goal of obtaining FDA approval and CE Mark to treat cluster headaches in 2024.
- Realeve has also been granted Breakthrough Device designation from the FDA with a goal of obtaining FDA approval and CE Mark to treat cluster headaches in 2024.
- We are also exploring its applications in other central nervous system disease conditions and excited about the potential,” states Dr. Peter Bonutti, founder and president, Realeve.
- This technology holds promise for addressing conditions like Alzheimer's, tumors, and other central nervous system disorders.
- The targeted therapy provides both pain relief, and can increase blood flow and medication delivery to the central nervous system.